Epidemiological, Clinical, Microbiological and Outcome Description of Patients With Klebsiella sp Meningitis (KlebsieLCR)

Klebsiella pneumoniae is implicated in the occurrence of severe pneumonia. Most Klebsiella pneumoniae infections are associated with care and occur in patients with compromised immune defenses. More recently, cases of hepatic abscess and acute community meningitis related to strains of Klebsiella pneumoniae have been reported. The mortality of these infections is important, most often due to a delayed diagnosis. The poor prognostic factors reported in the literature for very low numbers are: advanced age, coma, septic shock, glyceryachia <10mg / dL and proteinuria> 750 mg / dL. In addition, no study has specifically focused on the factors of occurrence and factors associated with Klebsiella sp. Indeed, meningitis related to Klebsiella pneumoniae seems to be a rare but probably underestimated event whose risk factors, clinical presentation, microbiological are little known and the treatment modalities of this severe infection are not codified.

Study Overview

• Status: Completed
• Conditions: Meningitis

• Study Type: Observational
• Enrollment (Actual): 132

Contacts and Locations

Study Locations

• France
  • Brest, France
    • CHU Brest
  • Caen, France
    • CHU caen
  • Créteil, France
    • Hopital Henri Mondor
  • Lyon, France
    • CHU Lyon
  • Nantes, France, 44093
    • CHU Nantes
  • Nice, France
    • CHU Nice
  • Paris, France, 75010
    • Hopital Lariboisiere
  • Paris, France
    • Hopital Necker Enfants Malades
  • Paris, France, 75014
    • Hopital Cochin
  • Paris, France, 75014
    • Groupe Hospitalier Paris Saint-Joseph
  • Paris, France
    • Hopital Foch
  • Paris, France
    • CHU Kremlin Bicêtre
  • Paris, France
    • Hopital Sainte Anne
  • Poitiers, France, 86000
    • CHU Poitiers
  • Reims, France
    • CHU Reims
  • Rennes, France, 35000
    • CHU Rennes
  • Strasbourg, France, 67000
    • CHU Strasbourg
  • Tours, France
    • Chu Tours

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patient with meningitis Klebsiella sp., hospitalized in one of the hospitals of the Clinical Microbiology Group between 2008 and 2018.

Description

Inclusion Criteria:

• Man or Woman whose age ≥ 18 years
• Patient with meningitis Klebsiella sp., hospitalized in one of the hospitals of the Clinical Microbiology Group
• Francophone patient

Exclusion Criteria:

• Patient under tutorship or curatorship
• Patient deprived of liberty
• Patient under safeguard of justice
• Patient opposing his participation

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Characterize meningitis with Klebsiella pneumoniae	This corresponds to characterize Klebsiella pneumoniae meningitis, portal entry, secondary infection, associated antibiotic and associated therapies and the clinical course of patients.	Day 1

Collaborators and Investigators

• Sponsor: Groupe Hospitalier Paris Saint Joseph
• Investigators: Study Director: Benoit PILMIS, MD, Groupe hospitalier Paris saint Joseph

Study record dates

Study Major Dates

• Study Start (Actual): July 5, 2019
• Primary Completion (Actual): December 31, 2019
• Study Completion (Actual): January 13, 2020

Study Registration Dates

• First Submitted: May 24, 2019
• First Submitted That Met QC Criteria: May 29, 2019
• First Posted (Actual): May 30, 2019

Study Record Updates

• Last Update Posted (Actual): August 23, 2021
• Last Update Submitted That Met QC Criteria: August 20, 2021
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Central Nervous System Diseases; Nervous System Diseases; Meningitis
• Other Study ID Numbers: KlebsieLCR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No